HomeCompareHEMCX vs JNJ

HEMCX vs JNJ: Dividend Comparison 2026

HEMCX yields 20.06% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HEMCX wins by $53.3K in total portfolio value
10 years
HEMCX
HEMCX
● Live price
20.06%
Share price
$9.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.3K
Annual income
$6,782.35
Full HEMCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — HEMCX vs JNJ

📍 HEMCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHEMCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HEMCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HEMCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HEMCX
Annual income on $10K today (after 15% tax)
$1,705.12/yr
After 10yr DRIP, annual income (after tax)
$5,765.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, HEMCX beats the other by $5,061.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HEMCX + JNJ for your $10,000?

HEMCX: 50%JNJ: 50%
100% JNJ50/50100% HEMCX
Portfolio after 10yr
$46.7K
Annual income
$3,805.06/yr
Blended yield
8.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HEMCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HEMCX buys
0
JNJ buys
0
No recent congressional trades found for HEMCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHEMCXJNJ
Forward yield20.06%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$73.3K$20.0K
Annual income after 10y$6,782.35$827.78
Total dividends collected$41.7K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HEMCX vs JNJ ($10,000, DRIP)

YearHEMCX PortfolioHEMCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,706$2,006.02$10,676$355.77+$2.0KHEMCX
2$15,978$2,382.10$11,407$389.39+$4.6KHEMCX
3$19,895$2,799.48$12,198$426.53+$7.7KHEMCX
4$24,546$3,257.90$13,056$467.62+$11.5KHEMCX
5$30,021$3,756.48$13,987$513.12+$16.0KHEMCX
6$36,416$4,293.75$14,998$563.56+$21.4KHEMCX
7$43,833$4,867.70$16,098$619.52+$27.7KHEMCX
8$52,377$5,475.79$17,295$681.69+$35.1KHEMCX
9$62,158$6,115.10$18,599$750.82+$43.6KHEMCX
10$73,292$6,782.35$20,022$827.78+$53.3KHEMCX

HEMCX vs JNJ: Complete Analysis 2026

HEMCXStock

The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of companies in emerging market countries. It may invest no more than 20% of its net assets in the securities of issuers in developed market countries. In addition, it may invest in securities issued by small- and mid-sized companies and in less seasoned issuers.

Full HEMCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this HEMCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HEMCX vs SCHDHEMCX vs JEPIHEMCX vs OHEMCX vs KOHEMCX vs MAINHEMCX vs ABBVHEMCX vs MRKHEMCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.